MitoQ for Fatigue in Multiple Sclerosis

• Status: Completed
• Trial end date: 2019-11-05
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine whether MS patients who receive Oral mitoquinone (MitoQ) have less fatigue than those receiving a placebo. A comparison between patient's fatigue scored at baseline and fatigue scored 12 weeks after drug initiation will assess if MitoQ has a significant change in fatigue.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Oregon Health and Science University
• Collaborator: MitoQ Ltd

Criteria

Inclusion Criteria:

• MS (any clinical subtype) as diagnosed by the 2010 McDonald criteria40;

• Expanded Disability Status Scale (EDSS) score of 2 to 8,

• Complaint of fatigue that has been persistent for at least two months;

• Modified Fatigue Impact Scale (MFIS) score of 38 or greater

Exclusion Criteria:

• Treatment with systemic glucocorticoids in the prior six weeks;

• Beck Depression Inventory (BDI) >31 (severe depression);

• Significant MS exacerbation in prior 30 days;

• Previous use of MitoQ or CoQ-10 within 30 days of screening appointment;

• Use of non-research-pharmacy-administered MitoQ or CoQ-10 during the duration of the study;

• Other significant health problem (e.g. active coronary heart disease, liver disease, pulmonary disease, diabetes mellitus) that might increase risk of patient experiencing adverse events),

• Pregnancy or intending to become pregnant or breastfeeding;

• Unable to complete the self-report forms;

• Unable to give informed consent;

• Prisoners will be excluded.

• Any condition which would make the patient, in the opinion of the investigator, unsuitable for the study.